Morgan Stanley Dyne Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,391,587 shares of DYN stock, worth $19.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,391,587

Previous 753,593 84.66%

Holding current value

$19.8 Million

Previous $17.8 Million 18.01%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$10.46 - $25.46 $6.67 Million - $16.2 Million	637,994 Added 84.66%	1,391,587 $14.6 Million
Q4 2024 Feb 14, 2025	SELL	$23.56 - $35.55 $7.06 Million - $10.7 Million	-299,669 Reduced 28.45%	753,593 $17.8 Million
Q3 2024 May 14, 2025	BUY	$31.94 - $47.04 $15.8 Million - $23.2 Million	494,210 Added 88.4%	1,053,262 $37.8 Million
Q3 2024 Nov 14, 2024	BUY	$31.94 - $47.04 $15.8 Million - $23.2 Million	494,210 Added 88.4%	1,053,262 $37.8 Million
Q2 2024 May 14, 2025	SELL	$23.65 - $35.63 $4.6 Million - $6.93 Million	-194,541 Reduced 25.82%	559,052 $19.7 Million
Q2 2024 Oct 17, 2024	SELL	$23.65 - $35.63 $9.53 Million - $14.4 Million	-403,112 Reduced 41.9%	559,052 $19.7 Million
Q2 2024 Aug 14, 2024	SELL	$23.65 - $35.63 $9.53 Million - $14.4 Million	-403,112 Reduced 41.9%	559,052 $19.7 Million
Q1 2024 Oct 17, 2024	BUY	$13.06 - $29.18 $5.26 Million - $11.8 Million	403,112 Added 72.11%	962,164 $27.3 Million
Q1 2024 Aug 16, 2024	SELL	$13.06 - $29.18 $13.8 Million - $30.9 Million	-1,059,231 Reduced 52.4%	962,164 $27.3 Million
Q1 2024 May 15, 2024	SELL	$13.06 - $29.18 $13.8 Million - $30.9 Million	-1,059,231 Reduced 52.4%	962,164 $27.3 Million
Q4 2023 Aug 16, 2024	BUY	$6.62 - $13.64 $9.68 Million - $19.9 Million	1,462,343 Added 261.58%	2,021,395 $26.9 Million
Q4 2023 Feb 13, 2024	BUY	$6.62 - $13.64 $12.7 Million - $26.1 Million	1,913,653 Added 1776.14%	2,021,395 $26.9 Million
Q3 2023 Nov 15, 2023	SELL	$8.6 - $12.18 $61,085 - $86,514	-7,103 Reduced 6.18%	107,742 $965,000
Q2 2023 Aug 14, 2023	BUY	$8.53 - $14.28 $10,363 - $17,350	1,215 Added 1.07%	114,845 $1.29 Million
Q1 2023 May 15, 2023	BUY	$10.88 - $15.0 $535,296 - $738,000	49,200 Added 76.36%	113,630 $1.31 Million
Q4 2022 Feb 14, 2023	SELL	$9.37 - $13.8 $610,080 - $898,518	-65,110 Reduced 50.26%	64,430 $746,000
Q3 2022 Nov 14, 2022	SELL	$7.2 - $15.17 $709,272 - $1.49 Million	-98,510 Reduced 43.2%	129,540 $1.65 Million
Q2 2022 Oct 27, 2022	SELL	$4.36 - $10.5 $333,509 - $803,176	-76,493 Reduced 25.12%	228,050 $1.57 Million
Q2 2022 Aug 15, 2022	SELL	$4.36 - $10.5 $333,509 - $803,176	-76,493 Reduced 25.12%	228,050 $1.57 Million
Q1 2022 Oct 27, 2022	BUY	$6.52 - $12.27 $498,734 - $938,569	76,493 Added 33.54%	304,543 $2.94 Million
Q1 2022 May 13, 2022	SELL	$6.52 - $12.27 $452,338 - $851,255	-69,377 Reduced 18.55%	304,543 $2.94 Million
Q4 2021 Feb 14, 2022	BUY	$11.89 - $16.07 $3.21 Million - $4.34 Million	270,142 Added 260.31%	373,920 $4.45 Million
Q3 2021 Nov 15, 2021	BUY	$15.6 - $21.46 $1.62 Million - $2.23 Million	103,778 New	103,778 $1.69 Million

Others Institutions Holding DYN

# of Institutions

216

Shares Held

116M

Call Options Held

322K

Put Options Held

66.2K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $737M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account